Login
Toggle sidebar

Lint: positron-emission-tomography-response-criteria-in-solid-tumors-percist-1

positron-emission-tomography-response-criteria-in-solid-tumors-percist-1
Isotope Notation
error

"complete resolution of 18F-FDG uptake within the measurable target lesion"

Line 7:27 · Write the isotope as symbol-mass, e.g. F-18, not '18F'.

"no new suspicious 18F-FDG avid lesions"

Line 14:26 · Write the isotope as symbol-mass, e.g. F-18, not '18F'.

"reduction of a minimum of 30% in target measurable tumour 18F-FDG SUL peak, with absolute drop in SUL of at least 0.8 SUL units"

Line 19:66 · Write the isotope as symbol-mass, e.g. F-18, not '18F'.

">30% increase in 18F-FDG SUL peak, with >0.8 SUL units increase in tumour SUL from the baseline scan in pattern typical of tumour and not of infection/treatment effect"

Line 30:25 · Write the isotope as symbol-mass, e.g. F-18, not '18F'.

"or visible increase in the extent of 18F-FDG tumour uptake"

Line 31:62 · Write the isotope as symbol-mass, e.g. F-18, not '18F'.

"or new 18F-FDG avid lesions typical of cancer and not related to treatment effect and/or infection"

Line 32:32 · Write the isotope as symbol-mass, e.g. F-18, not '18F'.
Acronyms
warning

"Positron Emission Tomography Response Criteria in Solid Tumours (PERCIST) are guidelines that use positron emission tomography (PET) to assess tumour metabolic response/viability."

Line 1:94 · 'PERCIST' has no definition. Spell it out if it's unfamiliar to the audience.

"As used below, SUL is the standardised uptake value corrected for lean body mass. SULpeak (or SULpeak) is the peak SUL in a spherical 1 cm3 volume of interest (VOI)."

Line 3:19 · 'SUL' has no definition. Spell it out if it's unfamiliar to the audience.

"As used below, SUL is the standardised uptake value corrected for lean body mass. SULpeak (or SULpeak) is the peak SUL in a spherical 1 cm3 volume of interest (VOI)."

Line 3:98 · 'SUL' has no definition. Spell it out if it's unfamiliar to the audience.

"As used below, SUL is the standardised uptake value corrected for lean body mass. SULpeak (or SULpeak) is the peak SUL in a spherical 1 cm3 volume of interest (VOI)."

Line 3:130 · 'SUL' has no definition. Spell it out if it's unfamiliar to the audience.

"if progression according to RECIST criteria, must verify with follow up"

Line 15:39 · 'RECIST' has no definition. Spell it out if it's unfamiliar to the audience.

"reduction of a minimum of 30% in target measurable tumour 18F-FDG SUL peak, with absolute drop in SUL of at least 0.8 SUL units"

Line 19:74 · 'SUL' has no definition. Spell it out if it's unfamiliar to the audience.

"reduction of a minimum of 30% in target measurable tumour 18F-FDG SUL peak, with absolute drop in SUL of at least 0.8 SUL units"

Line 19:106 · 'SUL' has no definition. Spell it out if it's unfamiliar to the audience.

"reduction of a minimum of 30% in target measurable tumour 18F-FDG SUL peak, with absolute drop in SUL of at least 0.8 SUL units"

Line 19:126 · 'SUL' has no definition. Spell it out if it's unfamiliar to the audience.

"no increase >30% of SUL or size in all other lesions"

Line 20:28 · 'SUL' has no definition. Spell it out if it's unfamiliar to the audience.

">30% increase in 18F-FDG SUL peak, with >0.8 SUL units increase in tumour SUL from the baseline scan in pattern typical of tumour and not of infection/treatment effect"

Line 30:33 · 'SUL' has no definition. Spell it out if it's unfamiliar to the audience.

">30% increase in 18F-FDG SUL peak, with >0.8 SUL units increase in tumour SUL from the baseline scan in pattern typical of tumour and not of infection/treatment effect"

Line 30:53 · 'SUL' has no definition. Spell it out if it's unfamiliar to the audience.

">30% increase in 18F-FDG SUL peak, with >0.8 SUL units increase in tumour SUL from the baseline scan in pattern typical of tumour and not of infection/treatment effect"

Line 30:82 · 'SUL' has no definition. Spell it out if it's unfamiliar to the audience.
Headings Valid
warning

Expected headings

  • H1 Terminology
  • H1 Usage
  • H1 Epidemiology
  • H2 Risk factors
  • H2 Associations
  • H1 Clinical presentation
  • H2 Complications
  • H1 Diagnosis
  • H2 Diagnostic criteria
  • H2 Diagnostic clues
  • H1 Pathology
  • H2 Aetiology
  • H2 Location
  • H2 Classification
  • H2 Macroscopic appearance
  • H2 Microscopic appearance
  • H2 Immunophenotype
  • H2 Markers
  • H2 Genetics
  • H1 Radiographic features
  • H2 Plain radiograph
  • H2 Mammography
  • H2 Antenatal ultrasound
  • H2 Transoesophageal echocardiography
  • H2 Ultrasound
  • H2 CT
  • H3 Dual-energy CT
  • H2 Angiography (DSA)
  • H2 MRI
  • H2 CT/MRI
  • H2 Nuclear medicine
  • H3 PET-CT
  • H3 PET-MRI
  • H1 Radiology report
  • H1 Treatment and prognosis
  • H2 Complications
  • H1 History and etymology
  • H1 Differential diagnosis
  • H2 Clinical differential diagnosis
  • H1 Practical points
  • H1 See also

"Complete metabolic response (CMR)"

Line 4:1 · "Complete metabolic response (CMR)" is not a recognised heading for this article type.

"Partial metabolic response (PMR)"

Line 17:1 · "Partial metabolic response (PMR)" is not a recognised heading for this article type.

"Stable metabolic disease (SMD)"

Line 23:1 · "Stable metabolic disease (SMD)" is not a recognised heading for this article type.

"Progressive metabolic disease (PMD)"

Line 28:1 · "Progressive metabolic disease (PMD)" is not a recognised heading for this article type.
Parentheses
suggestion

"The criteria consist of four categories: complete metabolic response (CMR), partial metabolic response (PMR), progressive metabolic disease (PMD), and stable metabolic disease (SMD)."

Line 2:73 · Use parentheses judiciously. There are at least 3 sets in this paragraph.
Links
0
0
0
0
0
0